Axinn Patent Attorneys Talk ACA Pushback and the BPCIA
May 4, 2020
The Center for Biosimilars
On May 4, Axinn partner Ted Mathias participated in a video interview with The Center for Biosimilars. He discussed the overall pushback to the Affordable Care Act (ACA) and what that means for the Biologics Price Competition and Innovation Act (BPCIA).
Click to access part 1, part 2, and part 3 of the interview.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
The Empty Chair in Antitrust Conspiracy Cases
Webinar
Antitrust
USC Gould/Analysis Group Global Competition Law Thought Leadership Conference
Speaking Engagement
Antitrust
17th ACI Summit on Biosimilars & Innovator Biologics
Speaking Engagement
Intellectual Property
GCR Live: Europe 2026
Speaking Engagement
Antitrust
20th Annual IBA Competition Mid-Year Conference
Speaking Engagement
Antitrust
Axinn Partners Named to Lawdragon 500 Leading Global Litigators 2026
News
Litigation & Trials
Turning Up the Heat: Federal Circuit Sets the Temperature for pH Measurements in Precedential Opinion
Axinn Viewpoints
Intellectual Property
Axinn Represents Tecomet in Closing of Merger with Orchid Orthopedic
Deals & Cases
Antitrust
Recent Benchmarking Suits Highlight DOJ Enforcement Risks
Byline Articles
Antitrust
“Old Crime, New Code” – DOJ Outlines its Views on When Software and AI Can Facilitate Collusion
Axinn Viewpoints
Antitrust
